PainChek Ltd (ASX:PCK) Secures $1.41M R&D Tax Refund, Advances FDA Review, and Launches Infant App
Financial Performance
PainChek Limited has received a $1.41 million R&D tax refund for the 2024 financial year, enhancing its financial runway to achieve upcoming key milestones.
FDA Review Progress
The US FDA review of PainChek’s Adult App is advancing, with a meeting scheduled for April 2025 and regulatory clearance expected in the first half of 2025. This approval would enable entry into the US healthcare market, presenting a potential opportunity valued at approximately USD $100 million annually in aged care.
Infant App Launch
PainChek has launched its PainChek® Infant app on the Apple App Store in Australia, priced at $99.99 per year. Early feedback from parents has been positive, validating the app’s value. A broader marketing rollout is planned for the second quarter of 2025.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.